PRODUCT LITERATURE

Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study

---

Bronchial asthma often remains uncontrolled despite treatment with inhaled corticosteroids (ICS), long-acting b2-agonists (LABA) or both, necessitating additional treatment. Patients 18 years (n Z 1681) with mild-to-moderate asthma received oral montelukast 10 mg added
to ICS or ICS þ LABAs, and were followed for 6 months in a prospective, open-label observational study. The primary endpoint was change in Asthma Control Test (ACT) score. Secondary endpoints included mini-Asthma Quality-of-Life Questionnaire (mini-AQLQ) and FEV1/PEF.
Mean ACT scores improved from 14.6 4.6 (baseline) to 19.4 4.4 (month 6; p < 0.0001). Using ACT score categories, the percentage of patients with uncontrolled (57.5%) or poorly controlled (25.0%) asthma at baseline decreased at month 6 (17.6 and 21.7%, respectively); the percentage of patients with well controlled (13.9%) or completely controlled (1.2%) asthma at baseline increased at month 6 (47.5 and 11.4%, respectively)

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Monarin

Specific Detail Info

Respiratory Medicine (2010) 104, 644e651

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment